Bristol-Myers Squibb and Hengrui Partner to Develop 13 Oncology and Immunology Drug Programs

Bristol-Myers Squibb Company (BMY) announces a groundbreaking collaboration with Hengrui Pharma aimed at developing a portfolio of 13 early-stage drug programs in oncology, hematology, and immunology. This strategic partnership allows Bristol Myers Squibb to leverage Hengrui's drug discovery capabilities in China while expanding its own pipeline to deliver innovative therapies for patients worldwide. The partnership includes exclusive rights to various assets, positioning both companies to address significant unmet medical needs effectively.

Collaboration Terms and Investment

Under the collaboration's terms, Bristol Myers Squibb commits to investing up to $950 million, which includes an upfront payment and further milestone-based payments. This agreement's total potential value could reach approximately $15.2 billion, depending on the success of the development, regulatory, and commercial milestones. This substantial investment underscores Bristol Myers Squibb's commitment to expanding its research and development efforts while also enhancing Hengrui’s global reach in the pharmaceutical landscape.

A Shared Vision for Innovation

The strategic alliance highlights both companies' shared objective of fostering innovation and addressing critical medical challenges. Frank Jiang, Hengrui's Executive Vice President, emphasizes the advantages of pooling their strengths to improve patient care globally. By collaborating on the development and commercialization of these promising assets, Bristol Myers Squibb and Hengrui position themselves to significantly impact the healthcare sector, addressing pressing healthcare needs and enhancing therapeutic options for patients. This partnership reflects Bristol Myers Squibb's ongoing strategy of disciplined portfolio management while advancing its mission to find innovative solutions to healthcare challenges.